Clinical features of hypermagnesemia in patients with functional constipation taking daily magnesium oxide
Mori H, Suzuki H, Hirai Y, Okuzawa A, Kayashima A, Kubosawa Y, Kinoshita S, Fujimoto A, Nakazato Y, Nishizawa T, Kikuchi M
Journal of clinical biochemistry and nutrition · 26 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Cross-sectional study (classified by our AI screen)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Possibly industry funded
- Authors
- At least one author declares a financial tie to industry
Based on full-text disclosure statement.
Publication
- Published
- 2019-01-01 · J Clin Biochem Nutr · vol. 65 · issue 1 · pp. 76–81
- Publisher
- Society for Free Radical Research Japan
- Cited
- 39 citations · more than 87% of similar papers · 2.3× the field average
- References
- 33 works
- Access
- Open access (free to publish)
- Research areas
- Magnesium in Health and Disease · Esophageal and GI Pathology · Biliary and Gastrointestinal Fistulas
- Keywords
- Hypermagnesemia, Magnesium, Medicine, Hypomagnesemia, Cathartic, Magnesium deficiency (plants), Laxative, Internal medicine, Constipation, Chemistry
11 authors
From JP
- Hideki MoriTokyo Medical Center; National Hospital Organization
- Hidekazu SuzukiTokai University
- Yuichiro HiraiTokyo Medical Center; National Hospital Organization
- Anna OkuzawaTokyo Medical Center; National Hospital Organization
- Atsuto KayashimaTokyo Medical Center; National Hospital Organization
- Yoko KubosawaTokyo Medical Center; National Hospital Organization
Abstract
Although magnesium oxide is widely used as a laxative, alterations in serum magnesium concentrations among patients taking daily magnesium oxide have not been clarified. The present retrospective, cross-sectional study investigated the risk factors for hypermagnesemia in patients taking daily oral magnesium oxide. Of 2,176 patients administered daily magnesium oxide, 193 (8.9%) underwent assays of serum magnesium concentrations and were evaluated. High serum magnesium concentration and hypermagnesemia were defined as serum magnesium concentrations ≥2.5 mg/dl and ≥3.0 mg/dl, respectively. Of the 193 patients taking daily magnesium oxide, 32 (16.6%) had high serum magnesium concentration and 10 (5.2%) had hypermagnesemia. Factors associated with hypermagnesemia included chronic kidney disease (CKD) grade 4 (p = 0.014) and magnesium oxide dosage (p = 0.009). Factors associated with high serum magnesium concentration included magnesium oxide dosage >1,000 mg/day (p = 0.004), CKD grades 4 (p = 0.000) and concomitant use of stimulant laxatives (p = 0.035). Age, however, was not associated with hypermagnesemia or high serum magnesium concentration. In conclusion, renal function and magnesium oxide dosage, but not age, were associated with hypermagnesemia and high serum magnesium concentration in patients with functional constipation taking daily magnesium oxide.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.